naltrexone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
opioid receptor antagonists/agonists related to normorphine	1765	16590-41-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: naltrexone cyclopropylmethylnoroxymorphone naltrel naltrexone hydrochloride naltrexone hydrochloride dihydrate naltrexone HCl	Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. Molecular weight: 341.41 Formula: C20H23NO4 CLOGP: 0.36 LIPINSKI: 0 HAC: 5 HDO: 2 TPSA: 70 ALOGS: -2.05 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

naltrexone
cyclopropylmethylnoroxymorphone
naltrel
naltrexone hydrochloride
naltrexone hydrochloride dihydrate
naltrexone HCl

Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

Molecular weight: 341.41
Formula: C20H23NO4
CLOGP: 0.36
LIPINSKI: 0
HAC: 5
HDO: 2
TPSA: 70
ALOGS: -2.05
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
50	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	100 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.44 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	22 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	7.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	57 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.79 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.90 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 20, 1984	FDA	TEVA WOMENS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Injection site reaction	2995.34	20.25	1033	20310	46816	46617903
Alcoholism	2249.82	20.25	442	20901	1776	46662943
Injection site mass	2241.33	20.25	632	20711	14408	46650311
Injection site pain	1101.18	20.25	655	20688	106497	46558222
Injection site induration	821.55	20.25	253	21090	7826	46656893
Drug dependence	507.01	20.25	225	21118	19676	46645043
Therapeutic response shortened	437.53	20.25	141	21202	5058	46659661
Feeling abnormal	323.44	20.25	339	21004	124721	46539998
Product administered at inappropriate site	230.96	20.25	72	21271	2311	46662408
Withdrawal syndrome	230.96	20.25	128	21215	18006	46646713
Inappropriate schedule of product administration	207.88	20.25	198	21145	64815	46599904
Injection site abscess	190.01	20.25	51	21292	948	46663771
Injection site swelling	185.40	20.25	151	21192	40176	46624543
Nausea	163.90	20.25	682	20661	686772	45977947
Drug use disorder	143.16	20.25	52	21291	2683	46662036
Anxiety	120.23	20.25	260	21083	181697	46483022
Injection site warmth	117.23	20.25	75	21268	13697	46651022
Insomnia	111.60	20.25	238	21105	164686	46500033
Product dose omission issue	106.97	20.25	237	21106	168283	46496436
Needle issue	105.43	20.25	52	21291	5752	46658967
Drug screen positive	102.21	20.25	45	21298	3846	46660873
Injection site nodule	98.40	20.25	42	21301	3329	46661390
Inadequate analgesia	95.24	20.25	39	21304	2785	46661934
Lack of injection site rotation	94.35	20.25	21	21322	169	46664550
Alcohol use	93.68	20.25	37	21306	2405	46662314
Substance abuse	89.86	20.25	42	21301	4125	46660594
Tremor	87.70	20.25	175	21168	115464	46549255
Headache	79.13	20.25	428	20915	477924	46186795
Product administration error	78.61	20.25	68	21275	19613	46645106
Pneumonia	78.61	20.25	37	21306	376283	46288436
Acute kidney injury	74.27	20.25	10	21333	235845	46428874
Depression	73.82	20.25	207	21136	169897	46494822
Euphoric mood	67.99	20.25	35	21308	4237	46660482
Alcohol poisoning	65.34	20.25	28	21315	2240	46662479
Lack of administration site rotation	64.29	20.25	10	21333	3	46664716
Dizziness	64.06	20.25	316	21027	340098	46324621
Injection site pruritus	62.88	20.25	84	21259	39659	46625060
Injection site discomfort	62.15	20.25	31	21312	3511	46661208
Injection site erythema	61.69	20.25	117	21226	74310	46590409
Anaemia	60.09	20.25	21	21322	255758	46408961
Rheumatoid arthritis	59.46	20.25	18	21325	240197	46424522
Necrosis ischaemic	59.33	20.25	20	21323	825	46663894
Injection site cyst	58.37	20.25	11	21332	33	46664686
Drug titration error	57.53	20.25	18	21325	584	46664135
Injection site cellulitis	56.71	20.25	21	21322	1144	46663575
Dependence	56.16	20.25	24	21319	1907	46662812
Body tinea	53.53	20.25	19	21324	916	46663803
Irritability	50.17	20.25	64	21279	28882	46635837
Imprisonment	46.21	20.25	12	21331	195	46664524
Pneumonia streptococcal	45.80	20.25	20	21323	1675	46663044
Inhibitory drug interaction	45.79	20.25	21	21322	1974	46662745
Hypotension	45.29	20.25	25	21318	232564	46432155
Magnesium deficiency	45.23	20.25	14	21329	438	46664281
Pregnancy	43.91	20.25	58	21285	27079	46637640
Injection site infection	43.77	20.25	19	21324	1568	46663151
Beta haemolytic streptococcal infection	43.72	20.25	20	21323	1869	46662850
Neutropenia	42.90	20.25	7	21336	143197	46521522
Injection site bruising	41.29	20.25	65	21278	35571	46629148
Thrombocytopenia	40.69	20.25	5	21338	126576	46538143
Panic attack	40.31	20.25	48	21295	20194	46644525
Dyspnoea	39.24	20.25	114	21229	515434	46149285
Alcohol abuse	38.08	20.25	19	21324	2153	46662566
Infection susceptibility increased	38.02	20.25	19	21324	2160	46662559
Feeling drunk	37.68	20.25	23	21320	3864	46660855
Crying	37.04	20.25	47	21296	21094	46643625
Poor quality sleep	36.87	20.25	40	21303	15213	46649506
Fatigue	36.84	20.25	432	20911	608265	46056454
Alcohol withdrawal syndrome	36.78	20.25	14	21329	823	46663896
Impaired work ability	35.67	20.25	36	21307	12600	46652119
Surgery	35.44	20.25	54	21289	28731	46635988
Food craving	35.34	20.25	15	21328	1172	46663547
Haemoglobin decreased	35.03	20.25	8	21335	128941	46535778
Apathy	35.02	20.25	28	21315	7240	46657479
Wrong technique in product usage process	34.94	20.25	77	21266	54345	46610374
Platelet count decreased	34.60	20.25	3	21340	100021	46564698
Pyrexia	34.57	20.25	67	21276	348735	46315984
Death	34.53	20.25	63	21280	335485	46329234
Oedema peripheral	34.35	20.25	15	21328	159691	46505028
Detoxification	34.27	20.25	6	21337	10	46664709
Sepsis	33.97	20.25	10	21333	136004	46528715
Impaired quality of life	33.54	20.25	20	21323	3222	46661497
Suicidal ideation	33.10	20.25	77	21266	56305	46608414
Illness	33	20.25	34	21309	12190	46652529
Feeling jittery	32.24	20.25	32	21311	10976	46653743
General physical health deterioration	31.81	20.25	7	21336	115762	46548957
Atrial fibrillation	31.16	20.25	5	21338	103585	46561134
Malabsorption from injection site	30.91	20.25	6	21337	22	46664697
Cough	30.75	20.25	36	21307	230213	46434506
Hospitalisation	30.28	20.25	80	21263	63305	46601414
Injection site necrosis	30.21	20.25	14	21329	1348	46663371
Drug withdrawal syndrome	29.06	20.25	48	21295	27336	46637383
Renal failure	29.01	20.25	8	21335	113586	46551133
Fall	28.61	20.25	68	21275	329029	46335690
Glucose tolerance impaired	28.51	20.25	21	21322	4810	46659909
Disease progression	28.39	20.25	4	21339	91296	46573423
Cardiac arrest	28.02	20.25	4	21339	90395	46574324
Mood altered	27.82	20.25	32	21311	12975	46651744
Toothache	27.67	20.25	36	21307	16556	46648163
Malaise	27.51	20.25	251	21092	330981	46333738
Pulmonary embolism	27.08	20.25	8	21335	108577	46556142
Condition aggravated	27.02	20.25	44	21299	245008	46419711
Somnolence	26.99	20.25	142	21201	156379	46508340
Cold sweat	26.97	20.25	29	21314	10916	46653803
Drug intolerance	26.91	20.25	17	21326	147032	46517687
Caffeine consumption	26.76	20.25	4	21339	0	46664719
Abnormal dreams	26.69	20.25	28	21315	10251	46654468
White blood cell count decreased	26.68	20.25	9	21334	112222	46552497
Hypersomnia	26.53	20.25	34	21309	15405	46649314
Feeling of despair	26.47	20.25	14	21329	1791	46662928
Restlessness	26.09	20.25	44	21299	25480	46639239
Restless legs syndrome	25.84	20.25	34	21309	15809	46648910
Aspartate aminotransferase increased	25.55	20.25	3	21340	78697	46586022
Adiposis dolorosa	25.35	20.25	8	21335	267	46664452
Migraine	25.34	20.25	80	21263	69946	46594773
Alanine aminotransferase increased	25.01	20.25	5	21338	88446	46576273
Urinary tract infection	24.79	20.25	39	21304	220227	46444492
Road traffic accident	24.43	20.25	41	21302	23650	46641069
Injection site irritation	23.88	20.25	18	21325	4269	46660450
Mass	23.80	20.25	28	21315	11625	46653094
Exposure during pregnancy	23.52	20.25	10	21333	108202	46556517
Hyponatraemia	22.61	20.25	9	21334	101323	46563396
Death of relative	22.47	20.25	7	21336	224	46664495
Blood creatinine increased	22.28	20.25	4	21339	76399	46588320
Product preparation issue	22.28	20.25	8	21335	399	46664320
Anger	21.79	20.25	27	21316	11825	46652894
Patient dissatisfaction with treatment	21.06	20.25	5	21338	55	46664664
Gastrointestinal haemorrhage	20.61	20.25	5	21338	77368	46587351
Blood glucose increased	20.51	20.25	4	21339	72009	46592710

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Injection site reaction	4568.28	26.50	1110	18104	9650	29923614
Injection site pain	2568.09	26.50	894	18320	29416	29903848
Alcoholism	2443.92	26.50	540	18674	2874	29930390
Injection site mass	1278.43	26.50	345	18869	4608	29928656
Drug dependence	880.91	26.50	374	18840	20921	29912343
Feeling abnormal	600.96	26.50	401	18813	56355	29876909
Therapeutic response shortened	598.49	26.50	178	19036	3422	29929842
Injection site induration	528.07	26.50	148	19066	2281	29930983
Withdrawal syndrome	340.53	26.50	159	19055	11091	29922173
Product administered at inappropriate site	311.95	26.50	90	19124	1545	29931719
Injection site swelling	303.12	26.50	136	19078	8644	29924620
Needle issue	284.46	26.50	103	19111	3729	29929535
Product dose omission issue	276.01	26.50	316	18898	91315	29841949
Insomnia	256.30	26.50	307	18907	93029	29840235
Drug use disorder	251.20	26.50	90	19124	3158	29930106
Inappropriate schedule of product administration	205.88	26.50	184	19030	39544	29893720
Alcohol use	178.57	26.50	73	19141	3682	29929582
Lack of injection site rotation	172.46	26.50	33	19181	69	29933195
Injection site discomfort	165.80	26.50	51	19163	1100	29932164
Depression	158.24	26.50	239	18975	90198	29843066
Drug screen positive	141.71	26.50	65	19149	4342	29928922
Anxiety	134.32	26.50	221	18993	89650	29843614
Pain	131.44	26.50	320	18894	172321	29760943
Acute kidney injury	126.94	26.50	14	19200	273828	29659436
Product administration error	117.63	26.50	87	19127	14290	29918974
Euphoric mood	115.56	26.50	56	19158	4234	29929030
Headache	111.12	26.50	311	18903	181995	29751269
Nausea	104.76	26.50	421	18793	296536	29636728
Dependence	98.66	26.50	35	19179	1191	29932073
Apathy	93.25	26.50	55	19159	6177	29927087
Drug withdrawal syndrome	93.22	26.50	87	19127	19722	29913542
Pneumonia	92.36	26.50	50	19164	334256	29599008
Malaise	92.16	26.50	275	18939	166687	29766577
Substance abuse	92.11	26.50	57	19157	6983	29926281
Irritability	89.30	26.50	91	19123	22959	29910305
Anaemia	88.23	26.50	14	19200	207978	29725286
Imprisonment	84.34	26.50	25	19189	473	29932791
Alcohol poisoning	80.41	26.50	42	19172	3722	29929542
Injection site abscess	79.70	26.50	26	19188	682	29932582
Yawning	73.16	26.50	23	19191	534	29932730
Feeling drunk	71.96	26.50	30	19184	1589	29931675
Injection site erythema	65.54	26.50	61	19153	13773	29919491
Emotional poverty	65.35	26.50	19	19195	335	29932929
Decreased appetite	63.72	26.50	226	18988	149684	29783580
Inadequate analgesia	62.99	26.50	32	19182	2676	29930588
Fatigue	62.24	26.50	384	18830	320289	29612975
Tremor	60.66	26.50	143	19071	75220	29858044
Injection site warmth	59.25	26.50	27	19187	1775	29931489
Injection site bruising	59.09	26.50	44	19170	7294	29925970
Injection site nerve damage	58.23	26.50	10	19204	7	29933257
Toxicity to various agents	57.42	26.50	21	19193	177162	29756102
Lack of administration site rotation	57.17	26.50	9	19205	0	29933264
Renal failure	56.19	26.50	8	19206	128958	29804306
Injection site nodule	54.83	26.50	24	19190	1434	29931830
Road traffic accident	54.78	26.50	61	19153	17010	29916254
Sepsis	51.56	26.50	15	19199	146380	29786884
Hypotension	51.00	26.50	33	19181	200532	29732732
Feeling of despair	50.64	26.50	20	19194	920	29932344
Depressed mood	49.81	26.50	58	19156	16971	29916293
Substance use disorder	49.18	26.50	12	19202	103	29933161
Atrial fibrillation	48.78	26.50	6	19208	108118	29825146
Thrombocytopenia	48.33	26.50	14	19200	137030	29796234
Neutropenia	47.46	26.50	12	19202	128528	29804736
Dyspnoea	46.33	26.50	90	19124	333205	29600059
Alcohol withdrawal syndrome	46.07	26.50	22	19192	1609	29931655
Haemoglobin decreased	45.44	26.50	9	19205	114089	29819175
Platelet count decreased	45.25	26.50	7	19207	106122	29827142
Pyrexia	43.13	26.50	77	19137	294412	29638852
Respiratory failure	42.10	26.50	7	19207	100635	29832629
Mood altered	40.27	26.50	37	19177	8213	29925051
Cardiac failure congestive	39.79	26.50	4	19210	84403	29848861
Disease progression	39.79	26.50	3	19211	79871	29853393
Anger	39.63	26.50	42	19172	11078	29922186
Injection site pruritus	39.46	26.50	31	19183	5561	29927703
Overdose	39.11	26.50	131	19083	84206	29849058
Blood creatinine increased	39.01	26.50	6	19208	91369	29841895
Condition aggravated	38.83	26.50	20	19194	137846	29795418
Toothache	38.41	26.50	31	19183	5780	29927484
Restlessness	38.36	26.50	59	19155	22540	29910724
Abdominal pain upper	37.21	26.50	106	19108	62445	29870819
Oedema peripheral	36.95	26.50	11	19203	105821	29827443
Cardiac failure	36.72	26.50	5	19209	83413	29849851
Substance use	36.57	26.50	13	19201	445	29932819
Sciatic nerve injury	35.21	26.50	9	19205	95	29933169
Myocardial infarction	34.23	26.50	19	19195	125606	29807658
Hypersomnia	33.86	26.50	39	19175	11277	29921987
General physical health deterioration	33.80	26.50	11	19203	99933	29833331
Gait disturbance	33.64	26.50	115	19099	74662	29858602
Energy increased	32.39	26.50	16	19198	1260	29932004
Injection site infection	31.88	26.50	14	19200	843	29932421
Hangover	31.85	26.50	15	19199	1063	29932201
Injection site inflammation	31.78	26.50	13	19201	656	29932608
Panic attack	31.31	26.50	33	19181	8648	29924616
Mood swings	31.15	26.50	31	19183	7595	29925669
Feeling jittery	30.81	26.50	23	19191	3825	29929439
White blood cell count decreased	30.65	26.50	8	19206	83939	29849325
Death of relative	30.33	26.50	6	19208	16	29933248
Thinking abnormal	30.26	26.50	26	19188	5285	29927979
Alcohol abuse	30.08	26.50	26	19188	5327	29927937
Hyperhidrosis	30.02	26.50	103	19111	66987	29866277
Muscle spasms	28.53	26.50	99	19115	64739	29868525
Migraine	28.28	26.50	38	19176	12836	29920428
Injection site cellulitis	28.21	26.50	11	19203	489	29932775
Product preparation error	28.02	26.50	16	19198	1690	29931574
Sluggishness	27.92	26.50	20	19194	3123	29930141
Chromaturia	27.57	26.50	39	19175	13826	29919438
Emotional disorder	27.13	26.50	24	19190	5070	29928194
Wrong technique in product usage process	27.10	26.50	61	19153	31094	29902170
Urinary tract infection	26.93	26.50	7	19207	73652	29859612
Opiates positive	26.86	26.50	9	19205	257	29933007

Pharmacologic Action:

Source	Code	Description
ATC	A08AA62	ALIMENTARY TRACT AND METABOLISM ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS Centrally acting antiobesity products
ATC	N02AA56	NERVOUS SYSTEM ANALGESICS OPIOIDS Natural opium alkaloids
ATC	N07BB04	NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS DRUGS USED IN ADDICTIVE DISORDERS Drugs used in alcohol dependence
FDA MoA	N0000000154	Opioid Antagonists
FDA EPC	N0000175691	Opioid Antagonist
MeSH PA	D000427	Alcohol Deterrents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D009292	Narcotic Antagonists
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
CHEBI has role	CHEBI:35488	cns depressants
CHEBI has role	CHEBI:35703	xenobiotic
CHEBI has role	CHEBI:50137	mu-opioid receptor antagonists
CHEBI has role	CHEBI:78298	environmental contaminants
CHEBI has role	CHEBI:90755	antidote to opioid overdose

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Alcoholism	indication	7200002
Severe pain	indication	76948002
Chronic pain	indication	82423001
Obesity	indication	414916001	DOID:9970
Prevention of opioid abuse	indication	426928008
Therapeutic opioid induced constipation	indication	136801000119102
Severe Pain with Opioid Tolerance	indication
Chronic Pain with Opioid Tolerance	indication
Neuropathic pain	off-label use	247398009
Suicidal thoughts	contraindication	6471006
Alcohol withdrawal delirium	contraindication	8635005
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Chronic disease of respiratory system	contraindication	17097001
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Hypercapnia	contraindication	29596007
Depressive disorder	contraindication	35489007
Acute hepatitis	contraindication	37871000
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Gastrointestinal ulcer	contraindication	40845000
Hypothyroidism	contraindication	40930008	DOID:1459
Low blood pressure	contraindication	45007003
Gastrointestinal perforation	contraindication	51875005
Paralytic ileus	contraindication	55525008	DOID:8442
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Substance abuse	contraindication	66214007
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Opioid dependence	contraindication	75544000	DOID:2559
Urethral stricture	contraindication	76618002
Decreased respiratory function	contraindication	80954004
Injury of head	contraindication	82271004
Cor pulmonale	contraindication	83291003	DOID:8515
Opioid withdrawal	contraindication	87132004
Disorder of biliary tract	contraindication	105997008	DOID:9741
Gastrointestinal obstruction	contraindication	126765001
Seizure disorder	contraindication	128613002
Drug-induced psychosis	contraindication	191483003	DOID:1742
Acute hepatic failure	contraindication	197270009
Acute pancreatitis	contraindication	197456007	DOID:2913
Impaired renal function disorder	contraindication	197663003
Disease of liver	contraindication	235856003	DOID:409
Chronic diarrhea	contraindication	236071009
Benign prostatic hyperplasia	contraindication	266569009
Primary malignant neoplasm of gastrointestinal tract	contraindication	363745004
Macrocolon	contraindication	367495003
Eosinophilic asthma	contraindication	367542003	DOID:9498
Primary adrenocortical insufficiency	contraindication	373662000
Severe diarrhea	contraindication	409587002
Central nervous system depression	contraindication	418072004
Acute exacerbation of asthma	contraindication	708038006
Increased Creatine Phosphokinase	contraindication
Pain in Opioid Naive Patients	contraindication
Opioid Use Within Last 4 Hours in Narcotic-Dependent Patient	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.31	acidic
pKa2	7.66	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN	ANTAGONIST	Ki	9.38	WOMBAT-PK	CHEMBL
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN	ANTAGONIST	Ki	8.93	WOMBAT-PK	CHEMBL
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN	ANTAGONIST	Ki	7.99	WOMBAT-PK	CHEMBL
Neuronal acetylcholine receptor subunit alpha-7	Ion channel	P36544	ACHA7_HUMAN		IC50	4.60	CHEMBL
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	6	DRUG MATRIX
Kappa-type opioid receptor	GPCR		OPRK_MOUSE		Ki	8.84	CHEMBL
Neuronal acetylcholine receptor subunit alpha-4	Ion channel		ACHA4_RAT		IC50	4.51	CHEMBL
Delta-type opioid receptor	GPCR		OPRD_MOUSE		Ki	7.91	CHEMBL
Mu-type opioid receptor	GPCR		OPRM_CAVPO		Ki	9.77	CHEMBL
Opioid receptor	GPCR		OPRD_RAT OPRK_RAT OPRM_RAT SGMR1_RAT		Ki	9.26	CHEMBL
Opioid receptors; mu and delta	GPCR		OPRD_MOUSE OPRM_MOUSE		Ki	9.06	CHEMBL
Mu-type opioid receptor	GPCR		OPRM_MOUSE		Ki	9.58	CHEMBL
Kappa-type opioid receptor	GPCR		OPRK_RAT		Ki	8.97	CHEMBL
Delta-type opioid receptor	GPCR		OPRD_RAT		Ki	8.32	CHEMBL
Mu-type opioid receptor	GPCR		OPRM_RAT		Ki	9.34	CHEMBL
Kappa-type opioid receptor	GPCR		OPRK_CAVPO		Ki	9.51	CHEMBL

External reference:

ID	Source
4019853	VUID
N0000147939	NUI
D02095	KEGG_DRUG
16676-29-2	SECONDARY_CAS_RN
4018545	VANDF
4019853	VANDF
C0027360	UMLSCUI
CHEBI:7465	CHEBI
CHEMBL19019	ChEMBL_ID
CHEMBL1201149	ChEMBL_ID
D009271	MESH_DESCRIPTOR_UI
DB00704	DRUGBANK_ID
1639	IUPHAR_LIGAND_ID
3368	INN_ID
5S6W795CQM	UNII
5485201	PUBCHEM_CID
105069	RXNORM
11621	MMSL
20600	MMSL
5151	MMSL
d01406	MMSL
001615	NDDF
004662	NDDF
373546002	SNOMEDCT_US
64191009	SNOMEDCT_US
87617007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
NULLLTREXONE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0406-1170	TABLET, FILM COATED	50 mg	ORAL	ANDA	15 sections
NULLLTREXONE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7036	TABLET, FILM COATED	50 mg	ORAL	ANDA	22 sections
EMBEDA	HUMAN PRESCRIPTION DRUG LABEL	2	16590-897	CAPSULE, EXTENDED RELEASE	0.80 mg	ORAL	NDA	14 sections
Naltrexone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-081	TABLET, FILM COATED	50 mg	ORAL	ANDA	23 sections
Naltrexone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42291-632	TABLET, FILM COATED	50 mg	ORAL	ANDA	25 sections
ContraveExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	2	43063-772	TABLET, EXTENDED RELEASE	8 mg	ORAL	NDA	30 sections
NULLLTREXONE HYDROCHLORIDE	Human Prescription Drug Label	1	47335-326	TABLET, FILM COATED	50 mg	ORAL	ANDA	22 sections
Naltrexone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2866	TABLET, FILM COATED	50 mg	ORAL	ANDA	27 sections
ContraveExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	2	50090-2945	TABLET, EXTENDED RELEASE	8 mg	ORAL	NDA	30 sections
NULLLTREXONE HYDROCHLORIDE	Human Prescription Drug Label	1	50090-3929	TABLET, FILM COATED	50 mg	ORAL	ANDA	23 sections
Naltrexone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4925	TABLET, FILM COATED	50 mg	ORAL	ANDA	23 sections
Naltrexone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	51224-206	TABLET, FILM COATED	50 mg	ORAL	ANDA	28 sections
ContraveExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	2	51267-890	TABLET, EXTENDED RELEASE	8 mg	ORAL	NDA	31 sections
Naltrexone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	53217-261	TABLET, FILM COATED	50 mg	ORAL	ANDA	25 sections
Naltrexone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5574	TABLET, FILM COATED	50 mg	ORAL	ANDA	26 sections
Addex-1000	HUMAN PRESCRIPTION DRUG LABEL	1	57377-010	PELLET, IMPLANTABLE	1000 mg	SUBCUTANEOUS	Export only	4 sections
Naltrexone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-1046	TABLET, FILM COATED	50 mg	ORAL	ANDA	27 sections
Naltrexone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-1047	TABLET, FILM COATED	50 mg	ORAL	ANDA	27 sections
NULLLTREXONE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	68084-291	TABLET, FILM COATED	50 mg	ORAL	ANDA	16 sections
Naltrexone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	68094-853	TABLET, FILM COATED	50 mg	ORAL	ANDA	26 sections
Naltrexone	HUMAN PRESCRIPTION DRUG LABEL	2	69364-3143	IMPLANT	200 mg	SUBCUTANEOUS	Unapproved drug other	25 sections
Naltrexone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	70518-1146	TABLET, FILM COATED	50 mg	ORAL	ANDA	23 sections
NULLLTREXONE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2718	TABLET, FILM COATED	50 mg	ORAL	ANDA	22 sections
Naltrexone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	71335-0014	TABLET, FILM COATED	50 mg	ORAL	ANDA	23 sections
NULLLTREXONE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	71335-1480	TABLET, FILM COATED	50 mg	ORAL	ANDA	15 sections
NULLLTREXONE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	76519-1160	TABLET, FILM COATED	50 mg	ORAL	ANDA	13 sections